The shares of the company: industry leader to maintain rapid growth

     Sina Tip: This article belongs to a stock comment column, only for securities consultants on the relevant stocks or plates of personal views and analysis, and informal news reports, Sina does not guarantee its authenticity and objectivity, investors operate on this basis, risk from the bear.　　For accurate information about the unit, please refer to the Bulletin of the Shanghai and Shenzhen Stock Exchange. Panorama Network Zhangmingfang 09 holding Gansu Reclamation-the most upstream of the raw materials planting and extraction, and increase the production of pharmaceutical anesthetics in Qinghai, construction of "anesthetic raw materials-raw materials-production-sales" complete industrial chain advantages, while grasping the opportunity of new medical reform to pull the drug market demand, to maintain the comparative monopoly of drugs leading advantage, The future profit growth of anesthetic business is expected to accelerate. Gansu Province is the State Council approved the country's only 1 legal cultivation of opium poppy, the extraction of narcotic raw materials "alkaloid" companies. Historically, the company has been working with it to maintain business cooperation, the 09 Gansu Agricultural land ownership reform, so both sides are interested in further increase to equity cooperation.　　The new medical reform expands the market demand of the medicine and operation anesthetic in our county and township, the company 09 cooperates with the Ministry of Health, the pharmacy organization, enlarges to the county, the township grass-roots general practitioner's anesthetic use training, seizes the opportunity. Beijing 09 began to the hospital and the community bundled tender, the company Beijing market depth of pure sales is very beneficial, the company will enter the community medical City in 09 will be the basic drugs to implement a unified procurement and direct distribution, at the same time, 09 began to implement a tertiary medical institutions unified tender. The company has with more than 340 hospitals in Beijing has long-term stability and good cooperation of the foundation, 09 through the policy opportunity to advance in Beijing community City Chang New health reform plan explicitly put forward to accelerate the development of commercial medical insurance, we expect China's high-end pharmaceutical market will continue to maintain rapid growth,　　Company distribution of varieties to the general agent and the total distribution of higher prices of imported drugs and joint ventures mainly, so the company's distribution business is also expected to maintain rapid growth. The company's development strategy "to value-added services to drive the sales of the three major business growth". The company has been working with the Beijing three hospitals to carry out drug information management cooperation, the future for the two level and community hospitals to provide technical support.　　At the beginning of 09, the company added sales staff 30~50 people, reduce the coverage of each sales staff, deepen value-added services. Company into a new round of rapid growth in the period of development, we anticipate the increase in the company's capital needs. 1, 09 new Logistics Center Two, to adapt to larger logistics scale and higher information management requirements. 2, 09 National Rui Pharmaceutical Capacity expansion, its leading products clindamycin phosphate has capacity bottlenecks, but also need to upgrade the GMP level. 3, holding Gansu reclamation. 4, further increase in Qinghai pharmaceutical shares.　　5, the acquisition of the Logistics center of the other shareholders of the equity. Maintain performance forecasts and A "strongly recommended-A" rating. We maintain the company's 2009-2011 sales revenue growth of 24%, 23% and 22%, net profit growth of 31%, 23% and 23%, considering the increase, Shang, realize EPs 0.53 Yuan, 0.65 yuan and 0.8 yuan, the companyExcellent management team, large shareholder state control support, is one of the strategic varieties of pharmaceutical business in China. State-controlled Beijing injects waiting time to mature.